



**COMPANY ANNOUNCEMENT**  
**16 March 2009**

### **NSL-043 PATENT GRANTED IN EUROPE**

NeuroDiscovery Ltd (ASX: NDL), a specialty neuroscience services provider and drug development Company, today announces that the key patent for its neuropathic pain development programme, NSL-043/SD118, has been granted in Europe and has now entered the national phase in key territories.

NSL-043/SD118 is being jointly developed by NeuroDiscovery and its wholly owned subsidiary NeuroSolutions Ltd under a collaboration agreement with Sosei concluded in June 2006. The patent was filed jointly by Sosei and NeuroSolutions Ltd and describes the use of this agent in the treatment of hyperalgesic conditions such as neuropathic pain.

NSL-043/SD118 was previously under clinical investigation in Japan for a different indication and demonstrated a potential new use as an oral therapy in neuropathic pain through a re-profiling collaboration. Phase I clinical trials have already been completed and good safety and tolerability were confirmed in both single ascending and multiple ascending dose studies.

**-ENDS-**

### **CONTACTS**

<b>Company</b>	
David McAuliffe Executive Director	Chris Moyses Chief Executive Officer
T: +61 (0)408 994 313	T: +44 (0)7802 586 573 (after 4pm AEST for UK time zone)
E: <a href="mailto:macdavid@iinet.net.au">macdavid@iinet.net.au</a>	E: <a href="mailto:CMoyes@neurosolutionsltd.com">CMoyes@neurosolutionsltd.com</a>

### **About NeuroDiscovery**

NeuroDiscovery Ltd is an ASX listed speciality neuroscience services provider and drug development company which owns 100% of NeuroSolutions Ltd (ASX Code NDL).

## **About NeuroSolutions**

NeuroSolutions Limited is a profitable service company, which has applied its broad spectrum expertise and drug discovery platforms to become a leading provider of specialised electrophysiological assays to the biopharmaceutical industry. Electrophysiology is a specialised technique which is used to record electrical activity in membranes, cells or tissues. NeuroSolutions' current clients include many established pharmaceutical and biotechnology companies.

In parallel to running its service business, the Company is also exploiting its in-house technologies and expertise for its own internal R&D and has a mature pipeline of programmes underway for the treatment of pain.

The Company has reported success in a Phase II trial for NSL-101. The Company also successfully completed two Phase I trials for the development compound NSL-043, in partnership with Sosei Co. Ltd. Both of these trials reported a successful outcome, facilitating further development.

*Except for historical information, this news release may contain forward-looking statements that reflect the Company's current expectation regarding future events. These forward looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.*